E.l.f. Beauty Stays Committed to China Amid Tariff Challenges

Published 15 hours agoELF

E.l.f. Beauty Stays Committed to China Amid Tariff Challenges

E.l.f. Beauty has decided to maintain its manufacturing footprint in China, even as the U.S. imposes a new 10% tariff on Chinese imports. This move affects the company's products manufactured in China. NBC New York reported that despite the challenges, CEO Tarang Amin expressed relief that the tariffs were kept at 10% and not increased to the previously suggested 60%.

In response to earlier tariffs, E.l.f. Beauty raised prices on a third of its products by $1 and is currently reevaluating its pricing strategy to address the new 10% tariff. The company has also been working on diversifying its supply chain, having decreased its dependency on Chinese manufacturing from almost 100% to around 80%, as noted by Retail Dive.

Looking ahead, E.l.f. Beauty intends to incorporate the impact of these tariffs into its fiscal 2026 outlook by exploring strategies such as supplier concessions and cost savings. While the company's focus remains on China for manufacturing, its strategic adjustments aim to sustain its competitive edge in the market.

Share this article

Twitter Facebook LinkedIn

Recent Articles

HSBC Commits $4 Billion to Boost Private Credit Funds

HSBC Commits $4 Billion to Boost Private Credit Funds

12 minutes agoHSBC

HSBC has announced a substantial $4 billion investment into its private credit funds, a move aimed at strengthening its role in the fast-evolving $2 trillion private credit market. According to Reuters, the funds will be channeled through HSBC Asset Management's alternative credit funds with the aim of attracting external capital and reaching a $50 billion credit fund milestone within five years. This strategic endeavor is part of CEO Georges Elhedery's broader plan to diversify HSBC's revenue streams as the bank faces challenges in maintaining profits from traditional lending. This pivot is seen as a response to the rapid growth of the private credit market, which industry insiders expect to swell to $3 trillion by 2028, notes a report by Brecorder. HSBC Asset Management has been active in the private credit space since 2018, successfully executing $7 billion across 150 deals. With this new infusion, HSBC targets global investments with a priority on direct lending in the UK and Asia. This move aligns with a wider industry trend where financial institutions are increasingly investing in private credit to bolster earnings and add diversity to their revenue bases, as highlighted by Reuters.

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

27 minutes agoSNY

Sanofi has recently announced its plan to acquire Blueprint Medicines for up to $9.5 billion, combining cash and stock elements. This strategic move is designed to boost Sanofi's portfolio in the immunology sector, allowing the pharmaceutical giant to integrate Blueprint Medicines' innovative therapies into its existing suite of offerings. The acquisition highlights Sanofi's strategic goal of strengthening its position in immunology, particularly through the incorporation of Blueprint Medicines' promising pipeline. This pipeline includes treatments for various immunological conditions, which aptly complements Sanofi's current portfolio. The deal's completion is contingent on customary regulatory approvals and is anticipated to close in the second half of 2025. Sanofi has expressed expectations that this transaction will be accretive to its earnings per share in the first year following the deal's closure. Sanofi's CEO underlined the alignment of Blueprint Medicines' assets with the company's focus on immunology, emphasizing the acquisition’s potential to address unmet medical needs. Notably, after the announcement, there was a slight dip in Sanofi's share price, as reported by Reuters, while Blueprint Medicines' shares experienced a modest uptick. This acquisition reaffirms Sanofi's dedication to enhancing its capabilities in the immunology field and bringing forward new treatments for patients globally.

Plus Therapeutics Posts Wider Than Expected Losses Despite Revenue Gains in Q1 2025

Plus Therapeutics Posts Wider Than Expected Losses Despite Revenue Gains in Q1 2025

42 minutes agoPSTV

Plus Therapeutics, Inc., trading under NASDAQ as PSTV, recently disclosed its financial results for the first quarter of 2025, revealing a GAAP EPS of -$1.19. This figure fell short of analyst expectations by $0.97, highlighting the firm’s struggle to meet financial forecasts. Despite this, the company managed to generate $1.06 million in revenue for the quarter. The company reported a net loss of $3.26 million, or $0.75 per share, which marks an improvement from last year's net loss of $4.81 million, or $2.07 per share. Operating losses also decreased from $4.7 million last year to $3.3 million this quarter. In terms of grants, Plus Therapeutics recognized $1.68 million in grant revenue, notably higher than the $0.51 million received in the same period of the previous year. However, their cash and investments balance saw a decline to $4.8 million as of March 31, 2025, down from $8.6 million at the end of 2024. In terms of clinical developments, Plus Therapeutics received FDA approval to start enrolling patients for their ReSPECT-LM trial targeting leptomeningeal metastases, which is set to begin in early 2025. This development is part of the company's broader strategy to advance its lineup of targeted radiotherapeutics for central nervous system cancers. The ongoing strategic efforts reflect Plus Therapeutics' commitment to overcoming financial and operational challenges while focusing on expanding its innovative therapeutic pipeline.

Apple Challenges EU's Digital Markets Act in New Appeal

Apple Challenges EU's Digital Markets Act in New Appeal

57 minutes agoAAPL

Apple has filed an appeal challenging the European Commission's interpretation of the interoperability requirements under the Digital Markets Act (DMA). The act mandates tech giants like Apple to open up certain features and information, such as WiFi pairing and system notifications, to third-party developers and non-Apple devices. These provisions aim to promote competition and improve user access to app functionalities. The Cupertino-based company has raised concerns that complying with these requirements would force it to disclose its intellectual property, potentially compromising user privacy and the seamless experience of its ecosystem. Apple has expressed that these regulations are not only cost-prohibitive but also pose a threat to innovation. A spokesperson from the company stated, "The EU's interoperability requirements threaten that foundation, while creating a process that is unreasonable, costly, and stifles innovation." This latest move by Apple comes amidst broader efforts by the European Union to reign in the dominance of major technology firms. While Apple contests the DMA rules, other tech companies reliant on Apple's App Store see these regulations as a means to ensure fair competition and a chance to enhance their offerings. This legal battle underscores the ongoing tension between big tech and regulatory bodies aiming to enforce stricter competition laws.